At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 target
Drug / intervention
NanoKnife Low Energy Direct Current (LEDC) System Ablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety Evaluation of the NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer - A Pilot Study
In Brief
A Phase 2 clinical trial evaluating NanoKnife Low Energy Direct Current (LEDC) System Ablation for Pancreatic Adenocarcinoma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma. Safety will be reviewed by means of analysis of adverse events, including serious adverse events, laboratory data, physician exam findings, and vital signs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Adenocarcinoma
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedJun 2011
Primary CompletionDec 2011
Study CompletionSep 2012
TodayJul 2026
First PostedJun 9, 2011
Enrollment StartMay 1, 2011
Primary CompletionDec 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.1 years ago
Interventions
NanoKnife Low Energy Direct Current (LEDC) System Ablationdevice
90 pulses of 70 microseconds each in duration will be administered per electrode pair.